Mark Andrews
Corporate Officer/Principal presso PharmaVentures Ltd.
Posizioni attive di Mark Andrews
Società | Posizione | Inizio | Fine |
---|---|---|---|
PharmaVentures Ltd.
PharmaVentures Ltd. Investment ManagersFinance Pharma Ventures Ltd. provides advisory services on life sciences transactions. It offers mergers and acquisitions, licensing, strategy and valuation, and expert services. The firm's industry coverage includes pharmaceuticals, biologics, drug delivery systems, diagnostics, medical devices, including telemedicine, medical software. The company is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | - | - |
Storia della carriera di Mark Andrews
Precedenti posizioni note di Mark Andrews
Società | Posizione | Inizio | Fine |
---|---|---|---|
Inventages Venture Capital Investment, Inc
Inventages Venture Capital Investment, Inc Investment ManagersFinance Inventages Venture Capital Investment, Inc (Inventages Venture) is a venture capital firm founded in 2000 by Gunnar Carsten Weikert. The firm is headquartered in Nassau with an additional office in London. | Corporate Officer/Principal | 01/01/2007 | 31/03/2015 |
DEWB AG (Venture Capital)
DEWB AG (Venture Capital) Investment ManagersFinance DEWB AG (Venture Capital) (DEWB-VC) is the venture capital subsidiary of Deutsche Effecten & Wechsel Beteiligungs AG (FR: EFF), headquartered in Jena, Germany. The firm, established in 1997, provides equity capital, corporate development expertise and network support to strong growth, medium-sized technology companies. | Investitore di Private Equity | 01/01/2001 | 30/12/2006 |
Biotech Venture Management LLC | Corporate Officer/Principal | - | - |
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Direttore/Membro del Consiglio | 02/12/2009 | - |
Formazione di Mark Andrews
University of Birmingham | Undergraduate Degree |
De Montfort University | Graduate Degree |
Statistiche
Distribuzione geografica
Regno Unito | 4 |
Bahamas | 2 |
Germania | 2 |
Posizioni
Corporate Officer/Principal | 3 |
Director/Board Member | 1 |
Graduate Degree | 1 |
Settori
Finance | 4 |
Consumer Services | 3 |
Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 5 |
---|---|
PharmaVentures Ltd.
PharmaVentures Ltd. Investment ManagersFinance Pharma Ventures Ltd. provides advisory services on life sciences transactions. It offers mergers and acquisitions, licensing, strategy and valuation, and expert services. The firm's industry coverage includes pharmaceuticals, biologics, drug delivery systems, diagnostics, medical devices, including telemedicine, medical software. The company is headquartered in Oxford, the United Kingdom. | Finance |
Inventages Venture Capital Investment, Inc
Inventages Venture Capital Investment, Inc Investment ManagersFinance Inventages Venture Capital Investment, Inc (Inventages Venture) is a venture capital firm founded in 2000 by Gunnar Carsten Weikert. The firm is headquartered in Nassau with an additional office in London. | Finance |
DEWB AG (Venture Capital)
DEWB AG (Venture Capital) Investment ManagersFinance DEWB AG (Venture Capital) (DEWB-VC) is the venture capital subsidiary of Deutsche Effecten & Wechsel Beteiligungs AG (FR: EFF), headquartered in Jena, Germany. The firm, established in 1997, provides equity capital, corporate development expertise and network support to strong growth, medium-sized technology companies. | Finance |
Biotech Venture Management LLC | |
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Health Technology |
- Borsa valori
- Insiders
- Mark Andrews
- Esperienza